Verified discoveries, trials, and approvals for this cancer type. Every story separates evidence strength, regulatory status, and guideline position.
In the randomized, open-label, phase 3 DeLLphi-304 trial, tarlatamab significantly extended overall survival compared with chemotherapy in patients with extensive-stage small cell lung cancer that had progressed after platinum-based chemotherapy…
Primary source cited
Last reviewed
An investigational NSCLC vaccine (BNT116) is being tested in an ongoing, open-label, first-in-human trial (estimated enrollment 320, sponsor BioNTech SE) with multiple treatment cohorts, primarily to establish safety (dose-limiting toxicities,…
Primary source cited
Last reviewed
In the randomized, placebo-controlled ADRIATIC trial, durvalumab given as consolidation therapy after concurrent chemoradiotherapy meaningfully extended both overall survival and progression-free survival compared with placebo in limited-stage small cell lung…
Primary source cited
Last reviewed
In the randomized, open-label, phase 3 DeLLphi-304 trial, tarlatamab significantly extended overall survival compared with chemotherapy in patients with extensive-stage small cell lung cancer that had progressed after platinum-based chemotherapy…
Primary source cited
Last reviewed
An investigational NSCLC vaccine (BNT116) is being tested in an ongoing, open-label, first-in-human trial (estimated enrollment 320, sponsor BioNTech SE) with multiple treatment cohorts, primarily to establish safety (dose-limiting toxicities,…
Primary source cited
Last reviewed
In the randomized, placebo-controlled ADRIATIC trial, durvalumab given as consolidation therapy after concurrent chemoradiotherapy meaningfully extended both overall survival and progression-free survival compared with placebo in limited-stage small cell lung…
Primary source cited
Last reviewed
Important: Eligibility and enrollment are not guaranteed, and listing here is not a treatment recommendation. Talk to your care team.
This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.
LuCa-MERIT-1 trial registry (BNT116). NCT05142189.
Eligibility varies — review trial criteria.
Regulatory approval is separate from evidence certainty and from guideline position. Approval applies only to the exact indication stated in each jurisdiction record.
DeLLphi-304 trial registry. NCT05740566.
Applies to the exact indication stated.
ADRIATIC trial primary results: durvalumab consolidation after chemoradiotherapy in LS-SCLC (NEJM). DOI 10.1056/NEJMoa2404873, PMID 39268857.
Applies to the exact indication stated.
CancerDiscoveries summarizes verified records in its database. Absence of a listing here does not establish that a treatment lacks regulatory authorization or access.